The IPSS-R has prognostic impact in untreated patients with MDS del(5q).

[1]  In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over time , 2015, British journal of haematology.

[2]  R. Schlenk,et al.  Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study. , 2014, Leukemia research.

[3]  A. Glasmacher,et al.  Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis , 2012, Leukemia.

[4]  Luca Malcovati,et al.  Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.

[5]  Z. Agur,et al.  Analyzing transformation of myelodysplastic syndrome to secondary acute myeloid leukemia using a large patient database , 2012, American journal of hematology.

[6]  R. Schlenk,et al.  Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study , 2012, Leukemia.

[7]  A. Carrió,et al.  Transfusion intensity, not the cumulative red blood cell transfusion burden, determines the prognosis of patients with myelodysplastic syndrome on chronic transfusion support , 2011, American journal of hematology.

[8]  C. Steidl,et al.  Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q , 2011, Leukemia.

[9]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.